By Caitlin Kramer, Research Analyst, LSN
Registration for RESI SF 2017 has been open for only a little over a month, and already 239 investors across 158 firms are registered. To illustrate who these 158 firms are, the below shows a breakdown of registered investment firm categories. VC firms have a large showing, followed by Corporate Venture groups and large pharmaceutical/biotech companies active in equity investing and early stage partnering.
Of the 239 investors registered thus far, 67% have a decision maker role at their firm, such as Director, VP, Partner or a C-Suite title. Only 16% are entry level investment professionals responsible for sourcing and preliminary screening. Of the remainder, most hold other managerial and sourcing roles; in addition, 6% of the investor attendees are angel investors. This abundance of active early stage life science investors and decision makers is unparalleled. Check out the below list of investors that have already registered, and keep in mind that many more will be added in the months leading up to the date of RESI SF on January 10th. We add new confirmed investors to the website every few days – keep up to date here. You have until Friday October 21st to sign up for RESI at the Earlybird rate – that’s tomorrow!